Heilmann, Romy M.;
Berghoff, Nora;
Mansell, Joanne;
Grützner, Niels;
Parnell, Nolie K.;
Gurtner, Corinne;
Suchodolski, Jan S.;
Steiner, Jörg M.
Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies
Beteiligte:
Heilmann, Romy M.;
Berghoff, Nora;
Mansell, Joanne;
Grützner, Niels;
Parnell, Nolie K.;
Gurtner, Corinne;
Suchodolski, Jan S.;
Steiner, Jörg M.
Erschienen:
Wiley, 2018
Erschienen in:Journal of Veterinary Internal Medicine
Sprache:
Englisch
DOI:
10.1111/jvim.15065
ISSN:
0891-6640;
1939-1676
Entstehung:
Anmerkungen:
Beschreibung:
<jats:sec><jats:title>Background</jats:title><jats:p>Calprotectin is a marker of inflammation, but its clinical utility in dogs with chronic inflammatory enteropathies (CIE) is unknown.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>Evaluation of fecal calprotectin in dogs with biopsy‐confirmed CIE.</jats:p></jats:sec><jats:sec><jats:title>Animals</jats:title><jats:p>127 dogs.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Prospective case‐control study. Dogs were assigned a canine chronic enteropathy clinical activity index (CCECAI) score, and histologic lesions severity was assessed. Fecal calprotectin, fecal S100A12, and serum C‐reactive protein (CRP) were measured. Food‐ or antibiotic‐responsive cases (FRE/ARE, n = 13) were distinguished from steroid‐/immunosuppressant‐responsive or ‐refractory cases (SRE/IRE, n = 20). Clinical response to treatment in SRE/IRE dogs was classified as complete remission (CR), partial response (PR), or no response (NR).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Fecal calprotectin correlated with CCECAI (ρ = 0.27, <jats:italic>P</jats:italic> = .0065) and fecal S100A12 (ρ = 0.90, <jats:italic>P</jats:italic> < .0001), some inflammatory criteria, and cumulative inflammation scores, but not serum CRP (ρ = 0.16, <jats:italic>P</jats:italic> = .12). Dogs with SRE/IRE had higher fecal calprotectin concentrations (median: 2.0 μg/g) than FRE/ARE dogs (median: 1.4 μg/g), and within the SRE/IRE group, dogs with PR/NR had higher fecal calprotectin (median: 37.0 μg/g) than dogs with CR (median: 1.6 μg/g). However, both differences did not reach statistical significance (both <jats:italic>P</jats:italic> = .10). A fecal calprotectin ≥15.2 μg/g separated both groups with 80% sensitivity (95% confidence interval [95%CI]: 28%‐100%) and 75% specificity (95%CI: 43%‐95%).</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Clinical Importance</jats:title><jats:p>Fecal calprotectin could be a useful surrogate marker of disease severity in dogs with CIE, but larger longitudinal studies are needed to evaluate its utility in predicting the response to treatment.</jats:p></jats:sec>